Trial reportHypertension (Dallas, Tex. : 1979)2011
Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months.
Trial report in Hypertension (Dallas, Tex. : 1979), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 5 registered trials, which are not on this map. Cited by 222 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Evaluation of Renal Denervation on Several Biological Variables in Patients With Uncontrolled Hypertension. An Observational Feasibility Study.
Impact of Patient-specific and Procedural Characteristics Like Catecholamine Spill-over on the Long-term Outcome After Renal Denervation and EP Ablation
A Randomized, Open-label Study Investigating the Effect of Bilateral Renal Artery Sympathetic Denervation by Catheter-based Radiofrequency Ablation on Blood Pressure and Disease Progression in Autosomal Dominant Polycystic Kidney Disease
Effects of Catheter Based Renal Sympathetic Denervation on Resistant Hypertension in End Stage Renal Disease in Korea
The Systemic Effects of Transcatheter Renal Artery Sympathetic Denervation Using a Second- Generation Radiofrequency Ablation Catheter: A Multicenter Observational Study.
Who cites it
222 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Renal denervation for resistant hypertension.The Cochrane database of systematic reviews · 2021Pooled it
- Renal denervation for resistant hypertension.The Cochrane database of systematic reviews · 2017Pooled it
- Renal denervation, adjusted drugs, or combined therapy for resistant hypertension: A meta-regression.Medicine · 2016Pooled it
- Renal sympathetic denervation for treatment of resistant hypertension: a systematic review.Journal of clinical hypertension (Greenwich, Conn.) · 2013Pooled it
- Renal artery denervation for treating resistant hypertension : definition of the disease, patient selection and description of the procedure.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2012Guideline
- Aorticorenal Ganglion Ablation Enhances Blood Pressure Reduction After Renal Denervation.Hypertension (Dallas, Tex. : 1979) · 2026Trial
- Clinical outcomes of laparoscopic-based renal denervation plus adrenalectomy vs adrenalectomy alone for treating resistant hypertension caused by unilateral aldosterone-producing adenoma.Journal of clinical hypertension (Greenwich, Conn.) · 2020Trial
- Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPLICITY HTN-2 randomized clinical trial.European heart journal · 2014Trial
- Changes in aortic pulse wave velocity in hypertensive postmenopausal women: comparison between a calcium channel blocker vs angiotensin receptor blocker regimen.Journal of clinical hypertension (Greenwich, Conn.) · 2012Trial
- Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 Trial.Clinical cardiology · 2012Trial
- Does Renal Sympathetic Denervation Impact the Outcome in Sepsis-Induced Shock? An Experimental Porcine Model.Journal of clinical medicine · 2026Article
- The role of intravascular imaging in optimizing renal denervation outcomes.Cardiology journal · 2026Review
- From resistant hypertension to renal denervation: an emerging therapeutic approach in light of new international guidelines.International journal of cardiology. Cardiovascular risk and prevention · 2025Review
- Increased plasma levels of erythropoietin after renal denervation in patients with resistant hypertension.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Article
- Central nervous system mechanisms of salt-sensitive hypertension.Physiological reviews · 2025Review
- Renal denervation achieves its antiarrhythmic effect through attenuating macrophage activation and neuroinflammation in stellate ganglia in chronic heart failure.Cardiovascular research · 2025Article
- Impact of sympathetic denervation via paraaortic lymphadenectomy on blood pressure in endometrial cancer patients.Turkish journal of obstetrics and gynecology · 2025Article
- Cardioneuroablation for the management of patients with recurrent vasovagal syncope and symptomatic bradyarrhythmias: the CNA-FWRD Registry.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2025Observational
- Impaired inhibitory reno-renal reflex responses in chronic kidney disease.Frontiers in physiology · 2025Article
- Cardiac Sympathetic Innervation and Ventricular Arrhythmias in Structural Heart Disease: Current Peripheral Neuromodulation Therapies and Emerging Therapeutic Targets.Arrhythmia & electrophysiology review · 2025Review
162 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renal sympathetic hyperactivity is seminal in the maintenance and progression of hypertension. Catheter-based renal sympathetic denervation has been shown to significantly reduce blood pressure (BP) in patients with hypertension. Durability of effect beyond 1 year using this novel technique has never been reported. A cohort of 45 patients with resistant hypertension (systolic BP ≥160 mm Hg on ≥3 antihypertension drugs, including a diuretic) has been originally published. Herein, we report longer-term follow-up data on these and a larger group of similar patients subsequently treated with catheter-based renal denervation in a nonrandomized manner. We treated 153 patients with catheter-based renal sympathetic denervation at 19 centers in Australia, Europe, and the United States. Mean age was 57±11 years, 39% were women, 31% were diabetic, and 22% had coronary artery disease. Baseline values included mean office BP of 176/98±17/15 mm Hg, mean of 5 antihypertension medications, and an estimated glomerular filtration rate of 83±20 mL/min per 1.73 m(2). The median time from first to last radiofrequency energy ablation was 38 minutes. The procedure was without complication in 97% of patients (149 of 153). The 4 acute procedural complications included 3 groin pseudoaneurysms and 1 renal artery dissection, all managed without further sequelae. Postprocedure office BPs were reduced by 20/10, 24/11, 25/11, 23/11, 26/14, and 32/14 mm Hg at 1, 3, 6, 12, 18, and 24 months, respectively. In conclusion, in patients with resistant hypertension, catheter-based renal sympathetic denervation results in a substantial reduction in BP sustained out to ≥2 years of follow-up, without significant adverse events.
Indexed as
Identifiers
21403086What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.